NewGenIVF Group surged 12.37% in premarket trading following the announcement that its board approved a one-for-three reverse stock split on December 23, 2025. The move, applicable to all share classes and not requiring shareholder approval, signals the company’s strategic effort to enhance share value and potentially improve liquidity. The reverse split is expected to consolidate the company’s capital structure, a development often viewed favorably by investors as it may indicate improved financial positioning or compliance with exchange requirements. While the split implementation date remains in the future, the approval itself has driven immediate optimism in the premarket session.
Comentarios
Aún no hay comentarios